The UKPDS risk engine: a model for the risk of coronary heart disease in Type II diabetes (UKPDS 56)
The DOI matches its Crossref record; 52 of the 52 references it cites were found in a registry or an index.
Abstract
A definitive model for predicting absolute risk of coronary heart disease (CHD) in male and female people with Type II diabetes is not yet available. This paper provides an equation for estimating the risk of new CHD events in people with Type II diabetes, based on data from 4540 U.K. Prospective Diabetes Study male and female patients. Unlike previously published risk equations, the model is diabetes-specific and incorporates glycaemia, systolic blood pressure and lipid levels as risk factors, in addition to age, sex, ethnic group, smoking status and time since diagnosis of diabetes. All variables included in the final model were statistically significant (P<0.001, except smoking for which P=0.0013) in likelihood ratio testing. This model provides the estimates of CHD risk required by current guidelines for the primary prevention of CHD in Type II diabetes.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“The lower the CAD risk, the higher the chance of a false positive”
From Exercise and Type 2 Diabetes (2010) · cites this paper as [248]
In the citing paper
“During the entire follow-up period, the rate of death among patients in the conventionaltherapy group was 50%, a finding that underscores the poor prognosis for such patients in the absence of intensive treatment.20”
From Effect of a multifactorial intervention on mortality in type 2 diabetes (2008) · cites this paper as [20]
Citations
Cites
Grundy, S. M., Bilheimer, D. W., Chait, A., Clark, L. T., Denke, M. A., Havel, R. J., Hazzard, W. R., Hulley, S. B., Hunninghake, D. B., Kreisberg, R. A., et al. (1993) · JAMA · doi:10.1001/jama.269.23.3015 · Cited by 27,947
(1998) · The Lancet · doi:10.1016/s0140-6736(98)07019-6 · Cited by 20,023
Self-citationStratton, I. M. (2000) · BMJ · doi:10.1136/bmj.321.7258.405 · Cited by 9,059
Self-citationPrevention of Coronary Heart Disease with Pravastatin in Men with Hypercholesterolemia
Shepherd, J., Cobbe, S. M., Ford, I., Isles, C. G., Lorimer, A. R., Macfarlane, P. W., McKillop, J. H., & Packard, C. J. (1995) · New England Journal of Medicine · doi:10.1056/nejm199511163332001 · Cited by 7,449
Stearne, M. R., Palmer, S. L., Hammersley, M. S., Franklin, S. L., Spivey, R. S., Lévy, J., Tidy, C. R., Bell, N. J., Steemson, J., Barrow, B. A., et al. (1998) · UCL Discovery (University College London) · Cited by 6,090
Downs, J. R., Clearfield, M., Weis, S., Whitney, E., Shapiro, D. R., Beere, P. A., Langendorfer, A., Stein, E. A., Kruyer, W., Gotto, Jr., et al. (1998) · JAMA · doi:10.1001/jama.279.20.1615 · Cited by 5,236
Blood pressure, stroke, and coronary heart disease
Collins, R., Peto, R., MacMahon, S., Godwin, J., Qizilbash, N., Collins, R., MacMahon, S., Hebert, P., Eberlein, K. A., Taylor, J. O., et al. (1990) · The Lancet · doi:10.1016/0140-6736(90)90944-z · Cited by 4,491
Cited by
Items 601–700 of 1,000
Here we go again … The metabolic syndrome revisited!
Sadikot, S. S., & Hermans, M. P. (2010) · Diabetes & Metabolic Syndrome Clinical Research & Reviews · doi:10.1016/j.dsx.2010.05.011 · Cited by 20
Prediction of morbidity and mortality in patients with type 2 diabetes
Wells, B. J., Roth, R., Nowacki, A. S., Arrigain, S., Yu, C., Rosenkrans, W. A., & Kattan, M. W. (2013) · PeerJ · doi:10.7717/peerj.87 · Cited by 18
Cost-Effectiveness of Implementing the Chronic Care Model for Diabetes Care in a Military Population
Kuo, S., Bryce, C. L., Zgibor, J. C., Wolf, D. L., Roberts, M. S., & Smith, K. J. (2011) · Journal of Diabetes Science and Technology · doi:10.1177/193229681100500305 · Cited by 19
Pollock, R. F., Valentine, W. J., Pilgaard, T., & Nishimura, H. (2010) · Journal of Medical Economics · doi:10.3111/13696998.2010.541045 · Cited by 20
Davies, A. K., McGale, N., Humphries, S. E., Hirani, S. P., Beaney, K. E., Bappa, D. A. S., McCabe, J. G., & Newman, S. P. (2015) · Trials · doi:10.1186/s13063-015-1073-7 · Cited by 18
“0) [28].”
Hu, W., & Lin, C. (2018) · Clinical Cardiology · doi:10.1002/clc.22991 · Cited by 22
Fernández-Silva, M. J., Alonso-González, A., González-Pérez, E., Gestal, J. J., & Grávalos, G. J. D. (2018) · Medicina de Familia SEMERGEN · doi:10.1016/j.semerg.2018.08.003 · Cited by 22
Jamthikar, A. D., Gupta, D., Khanna, N. N., Araki, T., Saba, L., Nicolaides, A. N., Sharma, A., Omerzu, T., Suri, H. S., Gupta, A. K., et al. (2020) · Elsevier eBooks · doi:10.1016/b978-0-12-819445-4.00015-1 · Cited by 18
Herman, W. H. (2003) · Diabetes Care · doi:10.2337/diacare.26.11.3182 · Cited by 21
Statin Therapy in Rheumatoid Arthritis
Costenbader, K. H., & Coblyn, J. S. (2005) · Southern Medical Journal · doi:10.1097/01.smj.0000161755.22998.f7 · Cited by 18
Lenz, M., & M�hlhauser, I. (2004) · Medizinische Klinik - Intensivmedizin und Notfallmedizin · doi:10.1007/s00063-004-1097-3 · Cited by 23
Eggleston, K. N., Shah, N. D., Smith, S. A., Berndt, E. R., & Newhouse, J. P. (2011) · American Economic Review · doi:10.1257/aer.101.3.206 · Cited by 18
“To measure quality (ΔV ), we use a clinically relevant metric: “modifiable cardiovascular risk” based on the equation for predicting cardiovascular complications from the United Kingdom Prospective Diabetes Study (UKPDS; Richard J. Stevens et al. 2001).”
MethodKatula, J. A., Kirk, J. K., Pedley, C. F., Savoca, M. R., Effoe, V. S., Bell, R. A., & Bertoni, A. G. (2017) · Contemporary Clinical Trials · doi:10.1016/j.cct.2016.12.005 · Cited by 17
“DSM) for changes in the 10-year UKPDS CVD risk [27] over the first year of intervention between arms.”
McQueen, R. B., Breton, M. D., Ott, M., Koa, H., Beamer, B., & Campbell, J. D. (2016) · Journal of Diabetes Science and Technology · doi:10.1177/1932296815599551 · Cited by 17
“Due to a lack of data in type 1 diabetes, for CHD, we used hazard rates derived from the UKPDS population of type 2 diabetes patients.(20) Transition probabilities for different SMBG error rates are based on the changes in HbA1c from Breton and Kovatchev.”
MethodGuazzo, A., Longato, E., Fadini, G., Morieri, M., Sparacino, G., & Camillo, B. D. (2023) · Scientific Reports · doi:10.1038/s41598-023-45115-1 · Cited by 12
Ronald, C. W., Tam, C. H. T., Hou, Y. J., Lau, E. S. H., Ozaki, R., Lui, J. N. M., Chow, E., Kong, A. P. S., Huang, C., Ng, A. C. W., et al. (2024) · Diabetologia · doi:10.1007/s00125-024-06299-x · Cited by 19
“These approaches include using clinical risk equations such as the UK Prospective Diabetes Study (UKPDS) risk engine [8], using contemporary risk models such as the Risk Equations for Complications Of type 2 Diabetes (RECODe) equations [3], use of biomarkers including genome-wide polygenic risk…”
Risk for cardiovascular events in an Italian population of patients with type 2 diabetes
Pellegrini, E., Maurantonio, M., Giannico, I. M., Simonini, M., Ganazzi, D., Carulli, L., D’Amico, R., Baldini, A., Loria, P., Bertolotti, M., et al. (2010) · Nutrition Metabolism and Cardiovascular Diseases · doi:10.1016/j.numecd.2010.02.022 · Cited by 17
Fritzen, K., Basinska, K., Rubio-Almanza, M., Nicolucci, A., Kennon, B., Vergès, B. L., Zakrzewska, K. E., & Schnell, O. (2019) · Journal of Diabetes Science and Technology · doi:10.1177/1932296819835172 · Cited by 18
Lee, S., Han, K., Kim, H., Cho, J., Yoon, K., & Kim, M. K. (2020) · Endocrinology and Metabolism · doi:10.3803/enm.2020.704 · Cited by 19
“Prospective Diabetes Study (UKPDS) risk engine is another popular risk model for CHD in subjects with type 2 diabetes [24].”
BackgroundOguoma, V. M., Coffee, N. T., Alsharrah, S. A., Abu‐Farha, M., Al-Refaei, F. H., Alkandari, A., Al-Mulla, F., & Daniel, M. (2021) · British Journal Of Nutrition · doi:10.1017/s0007114521000751 · Cited by 20
“These include, but are not limited to, the Framingham risk assessment tool(12), Finish diabetes risk score(13), systematic coronary risk evaluation risk charts(14), UK prospective diabetes study risk engine(15), European IR Risk Index and European HTN Risk Index(16).”
BackgroundPredictors Associated with Type 2 Diabetes Mellitus Complications over Time: A Literature Review
Elhefnawy, M. E., Ghadzi, S. M. S., & Harun, S. N. (2022) · Journal of Vascular Diseases · doi:10.3390/jvd1010003 · Cited by 24
Hasanreisoğlu, M., Robenshtok, E., Ezrahi, D., & Stiebel‐Kalish, H. (2013) · Neuroepidemiology · doi:10.1159/000342155 · Cited by 19
HDL in risk prediction and its direct and indirect involvement in atherogenesis
Durrington, P. N. (2002) · Atherosclerosis Supplements · doi:10.1016/s1567-5688(02)00042-9 · Cited by 18
Malik, S., Billimek, J., Greenfield, S., Sorkin, D. H., Ngo‐Metzger, Q., & Kaplan, S. H. (2012) · Medical Care · doi:10.1097/mlr.0b013e318273119b · Cited by 19
Valentine, W. J., Tucker, D., Silberman, C., Minshall, M. E., Palmer, A. J., & FOOS, V. (2008) · Value in Health · doi:10.1111/j.1524-4733.2008.00403.x · Cited by 18
Wu, Y., Chien, C.-L., Wang, S.-Y., Yang, W., & Wu, Y. (2013) · Journal of Women s Health · doi:10.1089/jwh.2012.4055 · Cited by 18
“It reinforced the importance of exercise challenge to detect the abnormality in MPI for women with DM.”
MethodInfluentialFhärm, E., Cederholm, J., Eliasson, B., Guðbjörnsdóttir, S., & Rolandsson, O. (2011) · Diabetic Medicine · doi:10.1111/j.1464-5491.2011.03425.x · Cited by 17
Olsson, M., Schnecke, V., Cabrera, C. S., Skrtic, S., & Lind, M. (2015) · Diabetes Care · doi:10.2337/dc14-2351 · Cited by 17
Safai, N., Carstensen, B., Vestergaard, H., & Ridderstråle, M. (2018) · BMJ Open · doi:10.1136/bmjopen-2017-019214 · Cited by 17
Park, G., An, H., Lee, S., Cho, Y., Gil, E. H., Her, S., Kim, Y., Lee, C. W., Koh, E. H., Lee, W. J., et al. (2015) · Medicine · doi:10.1097/md.0000000000000508 · Cited by 20
“Nonfatal CAD 10-year risk score was calculated by the UK Prospective Diabetes Study (UKPDS) risk engine.(15)”
BackgroundMethodNilsson, P. M., Cederholm, J., Guðbjörnsdóttir, S., & Eliasson, B. (2005) · Journal of Hypertension · doi:10.1097/01.hjh.0000188733.60345.78 · Cited by 17
Palmer, A. J., Roze, S., Valentine, W. J., Minshall, M. E., Lammert, M., Nicklasson, L., & Spinas, G. A. (2004) · Current Medical Research and Opinion · doi:10.1185/030079904x2033 · Cited by 17
Ogihara, T., Mita, T., Osonoi, Y., Osonoi, T., Saito, M., Tamasawa, A., Nakayama, S., Someya, Y., Ishida, H., Gosho, M., et al. (2017) · PLoS ONE · doi:10.1371/journal.pone.0173540 · Cited by 17
Horikawa, C., Aida, R., Tanaka, S., Kamada, C., Tanaka, S., Yoshimura, Y., Kodera, R., Fujihara, K., Kawasaki, R., Moriya, T., et al. (2021) · Nutrients · doi:10.3390/nu13020689 · Cited by 17
Takahara, M., Fujiwara, Y., Katakami, N., Sakamoto, F., Kaneto, H., Matsuoka, T., & Shimomura, I. (2014) · Atherosclerosis · doi:10.1016/j.atherosclerosis.2014.04.014 · Cited by 16
“It is true that male sex is often regarded as a classical risk factor for cardiovascular disease [28].”
BackgroundA Review of Cardiovascular Outcomes in the Treatment of People with Type 2 Diabetes
DAILEY, G. E., & Wang, E. (2014) · Diabetes Therapy · doi:10.1007/s13300-014-0091-x · Cited by 16
Jeong, I., Kim, S. G., Cho, D. H., Kim, C. H., Kim, C. S., Lee, W., Won, K. C., & Kim, D. M. (2016) · BMC Cardiovascular Disorders · doi:10.1186/s12872-016-0401-5 · Cited by 16
Moon, M. K., Noh, J., Rhee, E., Park, S. H., Kim, H. C., Kim, B. J., Kim, H. J., Choi, S., Na, J. O., Hyun, Y. Y., et al. (2023) · Diabetes & Metabolism Journal · doi:10.4093/dmj.2021.0344 · Cited by 16
“In addition, HT, or dyslipidemia, which frequently accompany DM as well as obesity, play more important roles in the development of CVD compared to obesity [27,28].”
BackgroundTucker, D. M. D., & Palmer, A. J. (2010) · Primary care diabetes · doi:10.1016/j.pcd.2010.10.001 · Cited by 26
Nagpal, J., & Bhartia, A. (2008) · Diabetic Medicine · doi:10.1111/j.1464-5491.2007.02307.x · Cited by 16
Parrinello, C. M., Matsushita, K., Woodward, M., Wagenknecht, L. E., Coresh, J., & Selvin, E. (2016) · Diabetes Obesity and Metabolism · doi:10.1111/dom.12686 · Cited by 18
“For instance, the UK Prospective Diabetes Study risk engine, a risk prediction tool for CHD and stroke in people with newly diagnosed diabetes [36,37], has been shown to greatly overestimate risk by up to fivefold in external populations [38].”
BackgroundRen, Y., Jin, N., Hong, T., Mu, Y., Guo, L., Ji, Q., Li, Q., Yang, X., & Ji, L. (2016) · Scientific Reports · doi:10.1038/srep36437 · Cited by 16
Refining Long-Term Prediction of Cardiovascular Risk in Diabetes – The VILDIA Score
Goliasch, G., Silbernagel, G., Kleber, M. E., Grammer, T. B., Pilz, S., Tomaschitz, A., Bartko, P. E., Maurer, G., Köenig, W., Niessner, A., et al. (2017) · Scientific Reports · doi:10.1038/s41598-017-04935-8 · Cited by 18
Betts, M. B., Milev, S., Hoog, M. M., Jung, H., Milenković, D., Qian, Y., Tai, M., Kutikova, L., Villa, G., & Edwards, C. (2018) · Value in Health · doi:10.1016/j.jval.2018.08.003 · Cited by 17
Association of T-wave abnormalities with major cardiovascular events in diabetes: the ACCORD trial
Mould, S., Soliman, E. Z., Bertoni, A. G., Bhave, P. D., Yeboah, J., & Singleton, M. J. (2021) · Diabetologia · doi:10.1007/s00125-020-05337-8 · Cited by 16
“curves for the UK Prospective Diabetes Study (UKPDS) [8] risk engine with and without the addition of TWA, according to the method of DeLong [9].”
MethodInfluentialManagement of dyslipidaemia in patients with type 2 diabetes in Australian primary care
Thomas, M. C., & Nestel, P. J. (2007) · The Medical Journal of Australia · doi:10.5694/j.1326-5377.2007.tb00835.x · Cited by 16
de Vries, F. M., Denig, P., Visser, S. T., Hak, E., & Postma, M. J. (2014) · Value in Health · doi:10.1016/j.jval.2013.12.010 · Cited by 19
Wan, Q., Harris, M., Davies, G. P., Jayasinghe, U. W., Flack, J. R., Georgiou, A., Burns, J. R., & Penn, D. L. (2007) · Australian Journal of Rural Health · doi:10.1111/j.1440-1584.2007.00916.x · Cited by 16
Framingham risk equations underestimate coronary heart disease risk in diabetes
Stevens, R., Coleman, R. L., & Holman, R. R. (2005) · Diabetic Medicine · doi:10.1111/j.1464-5491.2005.01387.x · Cited by 16
Self-citationAsimakopoulou, K. G., & Scambler, S. (2013) · European Diabetes Nursing · doi:10.1002/edn.228 · Cited by 15
Scherbaum, W. A., Goodall, G., Erny-Albrecht, K. M., Massi‐Benedetti, M., Erdmann, E., & Valentine, W. J. (2009) · Cost Effectiveness and Resource Allocation · doi:10.1186/1478-7547-7-9 · Cited by 15
“as the patient gets older, his/her risk of experiencing an event increases) [23-27].”
Lassen, M. C. H., Jensen, M. T., Biering‐Sørensen, T., Møgelvang, R., Fritz‐Hansen, T., Vilsbøll, T., Rossing, P. R., & Jørgensen, P. G. (2019) · European Heart Journal - Cardiovascular Imaging · doi:10.1093/ehjci/jez075 · Cited by 15
Cano, A., Llauradó, G., Albert, L., Mazarico, I., Astiarraga, B., González-Sastre, M., Martínez, L., Fernández‐Veledo, S., Simó, R., Vendrell, J. J., et al. (2020) · Journal of Clinical Medicine · doi:10.3390/jcm9072192 · Cited by 15
Mukonda, E. E., Cleary, S., & Lesosky, M. (2021) · BMC Health Services Research · doi:10.1186/s12913-021-07324-0 · Cited by 17
Masson, W. M., Barbagelata, L., Lavalle-Cobo, A., Lobo, M., Masson, G., Nogueira, J. P., & Vergès, B. L. (2022) · Diabetes & Metabolic Syndrome Clinical Research & Reviews · doi:10.1016/j.dsx.2022.102391 · Cited by 18
STOUGAARD, E. B., Rossing, P. R., Cherney, D. Z. I., Vistisen, D., & Persson, F. (2022) · Journal of Diabetes and its Complications · doi:10.1016/j.jdiacomp.2022.108257 · Cited by 15
Gianatti, E., Hoermann, R., Lam, Q. T., Dupuis, P., Zajac, J. D., & Grossmann, M. (2015) · Clinical Endocrinology · doi:10.1111/cen.12842 · Cited by 16
Judy, W. V., STOGSDILL, W. W., Judy, D., Judy, J., Sharma, P., Evans, M., & Guthrie, N. (2010) · Journal of Functional Foods · doi:10.1016/j.jff.2010.04.005 · Cited by 15
Denig, P., Dun, M. D., Schuling, J., Haaijer‐Ruskamp, F. M., & Voorham, J. (2012) · Trials · doi:10.1186/1745-6215-13-219 · Cited by 16
Síndrome metabólico, diabetes mellitus tipo 1 y resistencia a la insulina
Chillarón, J. J., Goday, A., & Pedro‐Botet, J. (2008) · Medicina Clínica · doi:10.1157/13118111 · Cited by 23
Noya, C., Chesla, C. A., Waters, C. M., & Alkon, A. (2019) · Western Journal of Nursing Research · doi:10.1177/0193945919845677 · Cited by 15
“The clinical significance is contextualized by the the UKPDS, which found that a 1% decrease in A1C values translated to a 14% decrease in macrovascular diseases, a 37% decrease in microvascular complications and a 21% decrease risk of deaths related to diabetes (Stevens et al., 2001).”
BackgroundCardiovascular disease risk prediction in type 1 diabetes: Accounting for the differences
Ruppert, K. M., Roberts, M. S., Orchard, T. J., & Zgibor, J. C. (2007) · Diabetes Research and Clinical Practice · doi:10.1016/j.diabres.2007.03.008 · Cited by 24
Cardiovascular Risk and the Metabolic Syndrome
Rutter, M., Meigs, J., & Wilson, P. (2006) · Metabolic Syndrome and Related Disorders · doi:10.1089/met.2006.4.252 · Cited by 21
Lee, J. D., Morrissey, J. R., & Patel, V. (2004) · Current Medical Research and Opinion · doi:10.1185/030079904125003539 · Cited by 15
Lee, S.-Y., Lai, H., Chua, Y. J., Wang, M. X., & Lee, G.-H. (2022) · Frontiers in Medicine · doi:10.3389/fmed.2022.880749 · Cited by 14
Ajjan, R., Bilir, S. P., Hellmund, R., & Souto, D. (2022) · Diabetes Therapy · doi:10.1007/s13300-022-01325-w · Cited by 14
Prediction models of diabetes complications: a scoping review
Ndjaboué, R., Ngueta, G., Rochefort-Brihay, C., Delorme, S., Guay, D., Ivers, N. M., Shah, B. R., Straus, S. E., Yu, C. H. Y., Comeau, S., et al. (2022) · Journal of Epidemiology & Community Health · doi:10.1136/jech-2021-217793 · Cited by 17
Assessment of Atherothrombotic Risk in Patients With Type 2 Diabetes Mellitus
Berg, D. D., Moura, F. A., Bellavia, A., Scirica, B. M., Wiviott, S. D., Bhatt, D. L., Raz, I., Bohula, E. A., Giugliano, R. P., Park, J., et al. (2023) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2023.04.031 · Cited by 14
Treatment Guidelines for Dyslipidemia: Summary of the Expanded Second Version
Son, J.-I., Chin, S. O., & Woo, J. (2012) · Journal of Lipid and Atherosclerosis · doi:10.12997/jla.2012.1.2.45 · Cited by 15
Exercise Stress Testing in Patients With Type 2 Diabetes: When Are Asymptomatic Patients Screened?
Harris, G. D., & White, R. D. (2007) · Clinical Diabetes · doi:10.2337/diaclin.25.4.126 · Cited by 17
Ezenwaka, C. E., Dimgba, A., Okali, F., Skinner, T. C., Extavour, R. M., Rodríguez, M. J., & Jones-LeCointe, A. (2011) · Nigerian Journal of Clinical Practice · doi:10.4103/1119-3077.79230 · Cited by 14
Cardiovascular morbidity and mortality in diabetes mellitus: prediction and prognosis.
Astrup, A. S. (2011) · PubMed · Cited by 15
Lee, A. A., Heisler, M., TRIVEDI, R. B., Obrosky, D. S., Mor, M. K., Piette, J. D., & Rosland, A.-M. M. (2020) · Annals of Behavioral Medicine · doi:10.1093/abm/kaaa081 · Cited by 14
Tominaga, Y., Morisky, D. E., & Mochizuki, M. (2021) · BMC Endocrine Disorders · doi:10.1186/s12902-021-00778-7 · Cited by 14
“HbA1c level [22], incidence of chronic kidney disease [23] and incidence of stroke and cardiovascular disease [24].”
BackgroundRosli, M. R., Wu, D. B., Neoh, C. F., & Karuppannan, M. (2021) · Journal of Medical Economics · doi:10.1080/13696998.2021.1889573 · Cited by 15
Multi-modality cardiac imaging in the management of diabetic heart disease
Wamil, M., Goncalves, M., Rutherford, A., Borlotti, A., & Pellikka, P. (2022) · Frontiers in Cardiovascular Medicine · doi:10.3389/fcvm.2022.1043711 · Cited by 12
“CAC is recognised as a better predictor of coronary artery events than the Framingham score and the UKPDS Risk Engine and has been shown to have much higher annual increase than in patients without diabetes.”
BackgroundSevero, M. D., Leiria, L. F., Ledur, P. D. S., Becker, A. D., Aguiar, F. M., Massierer, D., Gus, M., & Schaan, B. D. (2014) · Journal of Diabetes · doi:10.1111/1753-0407.12133 · Cited by 14
Ye, W., Isaman, D. J. M., & Barhak, J. (2010) · Information Fusion · doi:10.1016/j.inffus.2010.08.003 · Cited by 14
“CHD is defined in [8] as “the occurrence of fatal or non-fatal MI or sudden death”.”
BackgroundMethodInfluentialJiao, F. F., Lam, C. L. K., Fung, C. S. C., & McGhee, S. M. (2014) · Journal of Diabetes Investigation · doi:10.1111/jdi.12188 · Cited by 14
Lu, S., Beckles, G. L., Crosson, J. C., Bilik, D., Karter, A. J., Gerzoff, R. B., Lin, Y., Ross, S. V., McEwen, L. N., Waitzfelder, B. E., et al. (2012) · BMC Endocrine Disorders · doi:10.1186/1472-6823-12-12 · Cited by 15
“[3] 1 exp q 1 dt ð Þ=1 d f g;where d = 1.”
BackgroundMethodResultInfluentialThe role of pharmaceutical care in diabetes management
Davis, T. M. E., Clifford, R. M., Davis, W. A., & Batty, K. T. (2005) · The British Journal of Diabetes · doi:10.1177/14746514050050061001 · Cited by 14
Skrtic, S., Cabrera, C., Olsson, M., Schnecke, V., & Lind, M. (2017) · Heart · doi:10.1136/heartjnl-2016-309806 · Cited by 13
Yu, D., Shang, J., Cai, Y., Wang, Z., Zhang, X., Zhao, B., Zhao, Z., & Simmons, D. S. (2019) · BMJ Open Diabetes Research & Care · doi:10.1136/bmjdrc-2019-000735 · Cited by 14
Cost Effectiveness of Atorvastatin in Patients with Type 2 Diabetes Mellitus
Annemans, L., Marbaix, S., Webb, K., Gaal, L. V., & Scheen, A. J. (2010) · Clinical Drug Investigation · doi:10.2165/11531910-000000000-00000 · Cited by 14
“Patients’ characteristics (age, sex, smoking status, years since diagnosis of diabetes, lipid level and others) determine the probability of having a CHD or stroke event, such as described in the UKPDS (UK Prospective Diabetes Study) risk equations.([10,11]) By incorporating these risk equations, the model can produce…”
BackgroundBoesten, J. E. J., Kaper, J., Stoffers, J., Kroon, A. A., & van Schayck, O. C. P. (2012) · Family Practice · doi:10.1093/fampra/cms013 · Cited by 14
Gorter, K. J., Wens, J., Khunti, K., Cos, X., Topsever, P., Drivsholm, T., Jenum, A. K., Berkhout, C., Khalangot, M. D., Goldfracht, M., et al. (2010) · Primary care diabetes · doi:10.1016/j.pcd.2010.01.004 · Cited by 14
“The estimated absolute 10-year risk percentage of coronary heart disease (CHD) for persons without a history of cardiovascular events was calculated using the UKPDS risk engine [15].”
MethodVolmink, H., Bertram, M., Jina, R., Wade, A. N., & Hofman, K. J. (2014) · BMC Health Services Research · doi:10.1186/1472-6963-14-444 · Cited by 14
Beaney, K. E., Ward, C. E., Bappa, D. A. S., McGale, N., Davies, A. K., Hirani, S. P., Li, K., Howard, P., Vance, D. R., Crockard, M. A., et al. (2016) · Cardiovascular Diabetology · doi:10.1186/s12933-016-0457-7 · Cited by 14
“Ten-year risk of CHD was determined using the UKPDS score [8].”
MethodInfluentialRakhit, D. J., Downey, M., Jeffriess, L., Moir, S., Prins, J. B., & Marwick, T. H. (2005) · American Heart Journal · doi:10.1016/j.ahj.2005.01.029 · Cited by 14
IDRIS, I. R., Deepa, R., Fernando, D., & Mohan, V. (2008) · Diabetes Research and Clinical Practice · doi:10.1016/j.diabres.2008.04.006 · Cited by 14
A critical dialogue: communicating with type 2 diabetes patients about cardiovascular risk
Roach, P. J., & Marrero, D. G. (2005) · Vascular Health and Risk Management · doi:10.2147/vhrm.2005.1.4.301 · Cited by 16
Palmer, A. J., Roze, S., Lammert, M., Valentine, W. J., Minshall, M. E., Nicklasson, L., Gall, M.-A., & Spinas, G. A. (2004) · Current Medical Research and Opinion · doi:10.1185/030079904x2015 · Cited by 14
Microalbuminuria presents the same vascular risk as overt CVD in type 2 diabetes
Gimeno-Orna, J. A., Molinero-Herguedas, E., Sánchez-Vañó, R., Lou-Arnal, L. M., Juliani, B. B., & Castro-Alonso, F. J. (2006) · Diabetes Research and Clinical Practice · doi:10.1016/j.diabres.2006.03.008 · Cited by 16
Brändle, M., & Herman, W. H. (2004) · Current Medical Research and Opinion · doi:10.1185/030079904x1962 · Cited by 16
Cardio‐renal‐metabolic disease in primary care setting
Ibrahim, M. A., Ba-Essa, E. M., Baker, J. C., Cahn, A., Ceriello, A., Cosentino, F., Davies, M. J., Eckel, R. H., Gaal, L. V., Gæde, P., et al. (2023) · Diabetes/Metabolism Research and Reviews · doi:10.1002/dmrr.3755 · Cited by 14
Cardiovascular Risk Prediction Scores in Type 1 Diabetes
Erqou, S. A., Shahab, A., Fayad, F. H., Haji, M. S., Yuyun, M. F., Joseph, J., Wu, W., Adler, A., Orchard, T. J., & Echouffo-Tcheugui, J. B. (2024) · JACC Advances · doi:10.1016/j.jacadv.2024.101462 · Cited by 13
Self-citationTakahara, M., Katakami, N., Osonoi, T., Saitou, M., Sakamoto, F., Matsuoka, T., & Shimomura, I. (2015) · Journal of Atherosclerosis and Thrombosis · doi:10.5551/jat.29090 · Cited by 14
Ghim, J., Phương, N. T. T., Kim, M. J., Kim, E.-J., Song, G. S., Ahn, S., Shin, J., & Kim, E. (2019) · Drug Design Development and Therapy · doi:10.2147/dddt.s193254 · Cited by 13
“and dyslipidemia is approximately 80%, which means many people with type 2 diabetes mellitus also have dyslipidemia.(2) It is strongly recommended by the International Diabetes Federation Guideline Development Group to treat dyslipidemia in high-risk individuals with type 2 diabetes mellitus.”
BackgroundFarmer, A. A., Bobrow, K., Leon, N., Williams, N., Phiri, E., Namadingo, H., Cooper, S., Prince, J., Crampin, A. C., Besada, D., et al. (2019) · JMIR Research Protocols · doi:10.2196/12377 · Cited by 13
“Secondary clinical outcomes are the proportion of patients collecting 80% or more of their agreed-upon, diabetes-related medication derived from routine clinic data [22]; change in systolic blood pressure; change in lipids; a combined measure of cardiovascular risk based on HbA1c, lipids, and systolic blood pressure […”
BackgroundLee, A. A., Heisler, M., TRIVEDI, R. B., Leukel, P. J., Mor, M. K., & Rosland, A.-M. M. (2020) · Journal of Behavioral Medicine · doi:10.1007/s10865-020-00196-5 · Cited by 13
Metadata
- Authors
- STEVENS, R. J., KOTHARI, V., ADLER, A. I., & STRATTON, I. M.
- Affiliations
- University of Oxford (GB)
- Venue
- Clinical Science
- Publisher
- Portland Press Ltd.
- Published
- 2001-12-01
- Volume
- 101
- Issue
- 6
- Pages
- 671
- ISSN
- 0143-5221 (ISSN-L)
- OpenAlex
- W2117191092
- Cited by
- 1,084
- References
- 51
- Citations by year
- 2026: 3 · 2025: 4 · 2024: 10 · 2023: 33 · 2022: 44 · 2021: 60 · 2020: 46 · 2019: 42 · 2018: 47 · 2017: 42 · 2016: 39 · 2015: 60 · 2014: 66 · 2013: 68 · 2012: 59
- FWCI
- 12.67
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- Clinical Science (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes, Cardiovascular Risks, and Lipoproteins
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Management and Research
- Keywords
- coronary artery disease, type 2 diabetes, cardiovascular risk prediction, risk prediction model, glycemia, systolic blood pressure, serum lipids, primary prevention, smoking, sex differences
- MeSH terms
- Adult, Blood Pressure, Coronary Disease, Diabetes Mellitus, Type 2, Diabetic Angiopathies, Female, Follow-Up Studies, Glycated Hemoglobin, Humans, Lipids, Male, Middle Aged, Risk Factors, Smoking, Models, Statistical, Survival Rate, Risk Assessment
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.